AC Immune Updates Phase 2 Alzheimer's & Parkinson's Trials
Ticker: ACIU · Form: 6-K · Filed: Jan 3, 2024 · CIK: 1651625
| Field | Detail |
|---|---|
| Company | Ac Immune SA (ACIU) |
| Form Type | 6-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: clinical-trials, biotechnology, drug-development, pipeline-update
TL;DR
**AC Immune's Alzheimer's and Parkinson's drug trials are advancing, with key data expected throughout 2024.**
AI Summary
AC Immune SA, a Swiss biopharmaceutical company, filed a 6-K on January 3, 2024, providing a progress update on its Phase 2 active immunotherapy clinical pipeline for Alzheimer's and Parkinson's diseases. The company announced that its ABATE Phase 1b/2 trial for ACI-24.060 in Alzheimer's has completed enrollment for cohorts 1 and 2, with cohort 3 expected to finish in January 2024, and amyloid PET data anticipated in H1 and H2 2024. Additionally, its partner is launching the ReTain Phase 2b trial for ACI-35.030 in preclinical Alzheimer's, and the VacSYn Phase 2 trial for ACI-7104.056 in Parkinson's has completed cohort 1 enrollment and started cohort 2. This matters to investors because positive clinical trial results could significantly increase the stock's value, while delays or negative outcomes could lead to declines.
Why It Matters
This filing provides crucial updates on AC Immune's key drug candidates, directly impacting their potential market value and future revenue streams. Clinical trial progress is a primary driver of biotech stock performance.
Risk Assessment
Risk Level: medium — While progress is positive, clinical trials, especially in Phase 2, still carry significant risk of failure or delays, which could negatively impact the stock.
Analyst Insight
A smart investor would monitor the upcoming data releases for ACI-24.060 in H1 and H2 2024, as these will be significant catalysts for AC Immune's stock. They should also track the progress of the ReTain and VacSYn trials for further indications of pipeline strength.
Key Numbers
- January 3, 2024 — Filing Date (Date the 6-K report was filed and the press release was issued)
- H1 2024 — Expected Data Release (Anticipated release of 6-month amyloid PET data for ACI-24.060)
- H2 2024 — Expected Data Release (Anticipated release of 12-month amyloid PET data for ACI-24.060)
Key Players & Entities
- AC Immune SA (company) — the registrant and biopharmaceutical company
- Andrea Pfeifer (person) — Chief Executive Officer of AC Immune SA
- Christopher Roberts (person) — Chief Financial Officer of AC Immune SA
- ACI-24.060 (drug) — active immunotherapy for Alzheimer's disease in ABATE Phase 1b/2 trial
- ACI-35.030 (drug) — active immunotherapy for preclinical Alzheimer's disease in ReTain Phase 2b trial
- ACI-7104.056 (drug) — active immunotherapy for Parkinson's disease in VacSYn Phase 2 trial
Forward-Looking Statements
- AC Immune's stock price will experience volatility around the H1 and H2 2024 amyloid PET data releases for ACI-24.060. (AC Immune SA) — high confidence, target: H1 2024, H2 2024
- Further updates on the ReTain Phase 2b trial launch by AC Immune's partner will be a key focus for investors in the near term. (AC Immune SA) — medium confidence, target: Q1 2024
FAQ
What is the current status of the ABATE Phase 1b/2 trial for ACI-24.060?
The ABATE Phase 1b/2 trial for ACI-24.060 has completed enrollment for cohorts 1 and 2, and enrollment for cohort 3 is expected to be completed in January 2024.
When can investors expect to see amyloid PET data from the ABATE trial for ACI-24.060?
Investors can expect 6-month amyloid PET data in the first half of 2024 (H1 2024) and 12-month amyloid PET data in the second half of 2024 (H2 2024).
Which clinical trial is being launched by AC Immune's partner for preclinical Alzheimer's disease?
The ReTain Phase 2b clinical trial of ACI-35.030 in preclinical Alzheimer's disease is being launched now by AC Immune's partner.
What is the progress of the VacSYn Phase 2 trial for ACI-7104.056 in Parkinson's disease?
The VacSYn Phase 2 trial for ACI-7104.056 has completed enrollment of cohort 1 and has commenced cohort 2.
Who signed the 6-K report on behalf of AC Immune SA?
The 6-K report was signed by Andrea Pfeifer, Chief Executive Officer, and Christopher Roberts, Chief Financial Officer, on January 3, 2024.
Filing Stats: 235 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-01-03 16:19:30
Filing Documents
- dp204778_6k.htm (6-K) — 11KB
- dp204778_ex9901.htm (EX-99.1) — 17KB
- image_001.jpg (GRAPHIC) — 2KB
- 0000950103-24-000177.txt ( ) — 33KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Report on Form 6-K (other than Exhibit 99.1 hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333- 255576, File No. 333-227016 and File No. 333-249655) and Form S-8 (File No. 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Number Description 99.1 Press Release, dated January 3, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AC IMMUNE SA By: /s/ Andrea Pfeifer Name: Andrea Pfeifer Title: Chief Executive Officer By: /s/ Christopher Roberts Name: Christopher Roberts Title: Chief Financial Officer Date: January 3, 2024